Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
== Cancer == Cancer cells have irregularly shaped, large nucleoli, which may correspond ribosomal gene transcription up-regulation, and hence high cell proliferation. Oncogenes, like c-Myc, can upregulate rDNA transcription in a direct and indirect fashion. Tumor suppressors like Rb and p53, on the other hand, can suppress ribosome biogenesis. Additionally, the nucleolus is an important cellular sensor for stress and plays a key role in the activation of p53. Ribosomopathy has been linked to the pathology of various malignancies. Several ribosomopathies are associated with an increased rate of cancer. For example, both SDS and 5q- syndrome lead to impaired hematopoiesis and a predisposition to leukemia. Additionally, acquired defects in ribosomal proteins that have not been implicated in congenital ribosomopathies have been found in T-lymphoblastic leukemia/lymphoma, stomach cancer and ovarian cancer.
=== Determination of protein sequences === With their success in improving the analysis time for amino acids, Stein and Moore began to determine the structure of an entire protein molecule, specifically bovine ribonuclease, in the early 1950s. They determined the entire sequence of ribonuclease by 1960. This sequence combined with X-ray analysis of the crystallized ribonuclease lead to the determination of the nuclease's active site. Stein won a Nobel Prize in Chemistry in 1972 with Moore and Christian Boehmer Anfinsen, for their work on ribonuclease and "for their contribution to the understanding of the connection between chemical structure and catalytic activity of the ribonuclease molecule."
No relapse of flystrike occurred. Mules and others soon developed this serendipitous discovery into a technique now known as mulesing. During this operation, small strips of epidermis are peeled from a sheep's buttock using steel shears on either side of the anus and underside of the tail. This was formerly performed on mature sheep but it was later found that lambs recover more quickly and completely than older animals. Mulesing reduces the likelihood of flystrike by about 13 times. The practice became nearly universal during the 20th century. The success of animal rights movements in agitating for the procedure's curtailment has brought the proportion of Australian sheep ranchers who practice mulesing down to around 70% today.
== Occurrence == One or more bound protons are present in the nucleus of every atom. Free protons are found naturally in a number of situations in which energies or temperatures are high enough to separate them from electrons, for which they have some affinity. Free protons occur occasionally on Earth: thunderstorms can produce protons with energies of up to several tens of megaelectronvolt. Free protons exist in plasmas in which temperatures are too high to allow them to combine with electrons. Free protons of high energy and velocity make up 90% of cosmic rays, which propagate through the interstellar medium. Free protons are emitted directly from atomic nuclei in some rare types of radioactive decay. Protons also result (along with electrons and antineutrinos) from the radioactive decay of free neutrons, which are unstable.
Lyse the cells or tissue and isolate the mRNA molecules bound to ribosomes. Immobilize complexes. This is commonly performed with cycloheximide but other chemicals can be employed. It is also possible to forgo translation inhibitors with translation-incompetent lysis conditions. Using ribonucleases, digest the RNA not protected by ribosomes. Isolate the mRNA-ribosome complexes using sucrose gradient density centrifugation or specialized chromatography columns. Phenol/chloroform purification of mixture to remove proteins. Size-select for previously-protected mRNA fragments. Ligate 3' adapter to fragments. Reverse transcribe RNA to cDNA using reverse transcriptase. Circularize the cDNA Subtract known rRNA contaminants (optional). Amplify in strand-specific manner. Sequence reads. Align sequence results to genomic sequence to determine translational profile. Analyze resulting data using computational approaches specifically designed for ribosome profiling.
Sources: en.wikipedia.org
==== Identification ==== Calliphora vomitoria is often not the only species present at carrion, so some process of identification of the correct species is needed in order to avoid false estimates of the time of death due to their having different developmental cycles. In the past, simple morphological differences are used to differentiate between species. However, it is very difficult in crime scenes because more often than not these sites are not ideal, with preservation of insect species far from good. Methods that can best differentiate between the species are DNA, mitochondrial DNA, and the COI gene. The COI gene used in conjunction with restriction enzymes has been shown to be a relatively fast and simple method of distinguishing between blowfly species with good accuracy.
== Regulation == Glycogenolysis is regulated hormonally in response to blood sugar levels by glucagon and insulin, and stimulated by epinephrine during the fight-or-flight response. Insulin potently inhibits glycogenolysis. In myocytes, glycogen degradation may also be stimulated by neural signals; glycogenolysis is regulated by epinephrine and calcium released by the sarcoplasmic reticulum. Glucagon has no effect on muscle glycogenolysis. Calcium binds with calmodulin and the complex activates phosphorylase kinase.
=== Breast cancer === Clinical presentation of a lump in the breast is histologically viewed as a collagenous tumor or desmoplastic response created by myofibroblasts of the tumor stroma. Proposed mechanisms of activation of myofibroblasts are by immune cytokine signaling, microvascular injury, or paracrine signaling by tumor cells.
== Production == On 14 October 2025, it was announced via the shows official Instagram page, that casting for the fourth season was now open. Applications remained open for four weeks until closing on 6 November 2025. Ten contestants were announced on 24 April 2024. Participants include Malawitte, the Drag Race franchise's fifth cisgender female contestant. On the same day it was announced that Nicky Doll and Daphné Bürki would recur in their roles again during the season, while Loïc Prigent (who was already on the judging panel during the All Stars installment) and Anggun are joining the judging panel to take the place of Kiddy Smile.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.